Óscar M. Peiró a , b , c , c , Anna Carrasquer a , b , c , Raúl Sánchez-Gimenez a , b , c , Nisha Lal-Trehan a , b , c , Víctor del-Moral-Ronda a , b , c , Gil Bonet a , b , c , Isabel Fort-Gallifa d , Ester Picó-Plana d , Natalia Bastón-Paz d , Cristina Gutiérrez d , Alfredo Bardaji a , b , c
18 January 2021
The aim of our study was to analyse the short-term prognostic value of different biomarkers in patients with COVID-19.
We included patients admitted to emergency department with COVID-19 and available concentrations of cardiac troponin I (cTnI), D-dimer, C-reactive protein (CRP) and lactate dehydrogenase (LDH). Patients were classified for each biomarker into two groups (low vs. high concentrations) according to their best cut-off point, and 30-day all-cause death was evaluated.
After multivariate adjustment, cTnI ≥21 ng/L, D-dimer ≥1112 ng/mL, CRP ≥10 mg/dL and LDH ≥334 U/L at admission were associated with an increased risk of 30-day all-cause death (hazard ratio (HR) 4.30; 95% CI 1.74–10.58; p = 0.002; HR 3.35; 95% CI 1.58–7.13; p = 0.002; HR 2.25; 95% CI 1.13–4.50; p = 0.021; HR 2.00; 95% CI 1.04–3.84; p = 0.039, respectively). The area under the curve for cTnI was 0.825 (95% CI 0.759–0.892) and, in comparison, was significantly better than CRP (0.685; 95% CI 0.600–0.770; p = 0.009) and LDH (0.643; 95% CI 0.534–0.753; p = 0.006) but non-significantly better than D-dimer (0.756; 95% CI 0.674–0.837; p = 0.115).